Israel’s Oramed has signed a deal worth $50 million that gives China’s Hefei Life Science & Technology (HLST) the rights to Oramed’s oral insulin capsule ORMD-0801 in China, Hong Kong and Macau. ORMD-0801 will help treat the large and growing numbers of diabetics in China.
http://www.timesofisrael.com/oramed-inks-huge-50m-deal-with-chinese-pharma-firm/